Aptus Pharma IPO Allotment Status Live Today: Step-by-Step Guide To Check Your Status

Ahmedabad, September 26, 2025: Finalisation of the basis of allotment for Aptus Pharma Limited is expected to happen today for its SME IPO on BSE SME. Here is how you can check your allotment  through the registrar’s portal and on the BSE website  and what comes next for refunds and demat credits.

How to Check Aptus Pharma IPO Allotment Status on Registrar’s website (Bigshare)

• Visit the IPO Allotment Status page of the registrar, Bigshare Services Private Limited: https://www.bigshareonline.com/ipo_allotment.html
• Choose any server to check allotment status
• Choose “Aptus Pharma Limited” from the issue dropdown
• Enter any of the following: PAN (as per your demat), Application Number, or DP ID / Client ID (NSDL or CDSL)
• Submit to see your status

If allotted, you will be able to see the number of shares allotted. If not allotted, the status will reflect no allotment.

Note: Bigshare is the Registrar to the Issue for Aptus Pharma.

How to Check Aptus Pharma IPO Allotment Status on the BSE Website

• Go to BSE’s “Status of Issue Application” page for equity IPOs: https://www.bseindia.com/investors/appli_check.aspx
• Issue Type: Choose Equity
• Issue Name: Choose Aptus Pharma Limited
• Input Application Number or PAN, then click to see your status

What Happens After Allotment

Unblocking of funds: Non-allottees see ASBA blocks unblocked following the basis of allotment and issuer instruction to the SCSB as part of the normal IPO procedure.

Demat credit: Successful investors’ demat accounts are credited with allotted shares after corporate action upon finalisation of allotment.

T+3 timeline: Listing after the issue follows the condensed T+3 cycle currently applicable for public issues.

Aptus Pharma IPO Anchor Allocation

Aptus Pharma issued 5,28,000 shares at ₹70 per share during the anchor round. Allotment was done to 31 Degrees North Fund – Fund I (1,92,000 shares), Eminence Global Fund PCC – Eubilía Capital Partners Fund I (1,92,000 shares), and Zeal Global Opportunities Fund (1,44,000 shares).

Aptus Pharma IPO Subscription Snapshot

The book concluded with robust demand in categories, particularly retail and HNI investors. Subscription was at 31.54x in the category of Retail Individual Investors (RII), 21.51x in the Non-Institutional Investors (NII) segment, and 1.24x in Qualified Institutional Buyers (QIBs). Total subscription was at 20.82x, with bids mostly at the higher band of ₹70.

Aptus Pharma IPO Lead Manager & Registrar

Aptus Pharma IPO was handled by Interactive Financial Services Limited as Book Running Lead Manager, and Bigshare Services Private Limited acted as the Registrar to the Issue. The shares are to be listed on the SME Platform of BSE, which is the stock exchange of choice.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations